Covid 19 Research using Clinical Trials (Home Page)
HP:0000716: DepressivityHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1106 | Questionnaire to study the psychological impact of confinement Wiki | 0.45 |
| drug1353 | Taste test Wiki | 0.45 |
| drug940 | Online survey Wiki | 0.45 |
| drug239 | CONVALESCENT PLASMA Wiki | 0.45 |
| drug109 | Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery Wiki | 0.45 |
| drug981 | Pandemic control measures Wiki | 0.45 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003866 | Depressive Disorder NIH | 1.00 |
| D003863 | Depression, NIH | 0.60 |
| D019964 | Mood Disorders NIH | 0.45 |
| D019052 | Depression, Postpartum NIH | 0.32 |
| D001008 | Anxiety Disorders NIH | 0.14 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 5 clinical trials
Clinical Trials
1 Using a Diagnostic Taste Test as a Surrogate Biomarker to Predict Drug Effectiveness in Patients With Depression (MDD)
The study will be looking at whether a taste test device can be used as a diagnostic aid for depression. Taste tests will be carried out before and after first use of an antidepressant (prescribed by the patient's GP) and then again a month later a further taste test will be conducted. The results of these tests will be assessed to see if they correlate with the outcome of validated mood questionnaires carried out at the first and second visits.
NCT03645447 Depression Diagnostic Test: Taste test MeSH:Depression Depressive Disorder
HPO:Depressivity
Primary Outcomes
Description: Change in taste threshold measures (sweet, salt, bitter, sour) between baseline and post-probe(s) at day 1 and 28 days after antidepressant treatment is initiated is assessed with the assistance of a taste test device.
Measure: Change in taste threshold with antidepressant treatment Time: 4-6 weeks (per patient)
Description: Change in mood (assessed by score on the Beck Depression Inventory (BDI)) with antidepressant treatment is assessed. BDI scores may range from 0-63, where 0 demonstrates the lowest depression score and 63 the most severe depression.
Measure: Change in mood (assessed by score on the Beck Depression Inventory) with antidepressant treatment Time: 4-6 weeks (per patient)
Secondary Outcomes
Description: Changes in scores on the Clinical Global Impression scale, as assessed by the participant's general medical practitioner is recorded. This scale ranges from 0-7, where 0 is the least severely ill and 7 the most severely ill.
Measure: Change in mood with antidepressant treatment, measured by the Clinical Global Impression Scale (CGI scale) Time: 4-6 weeks (per patient)
Description: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9). PHQ9 scores range from 0-27, where 0 is the score for the least depressed patients and 27 the most severely depressed patients.
Measure: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9) Time: 4-6 weeks (per patient)
Description: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS). HADS scores for depression range from 0-21, where 0-7 is normal, 8-10 borderline and 11+ indicates clinical depression
Measure: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS) Time: 4-6 weeks (per patient)
Description: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS). Scores for QIDS range from 0-27, where 0 indicates no symptoms of depression and 27 indicates the most severe depression.
Measure: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS) Time: 4-6 weeks (per patient)
Description: A computerised algorithm will be used to direct the taste test to assess taste sensitivity. The algorithm has been developed to direct the taste test, indicating which taste solutions should be presented to the participant in which order. Every solution presented is recorded, along with answers given. These will be examined after testing to validate the code's ability to follow the algorithm created and properly determine taste thresholds.
Measure: Validation of diagnostic algorithm, comparing the sequence of taste testing determined by the device software with the algorithm described in the software specification. Time: 12 months (duration of trial)
Description: User views on ease of use of the device and testing process will be collected. Users will be asked to give ease of use a score from 1-5, where 1 is very easy and 5 is very difficult. Participants will also be asked whether they would use the taste test again.
Measure: User assessment of ease of use of the device and testing process. Time: 4-6 weeks (per patient)
2 Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression
Primary Outcomes
Description: Change in taste threshold measures (sweet, salt, bitter, sour) between baseline and post-probe(s) at day 1 and 28 days after antidepressant treatment is initiated is assessed with the assistance of a taste test device.
Measure: Change in taste threshold with antidepressant treatment Time: 4-6 weeks (per patient)Description: Change in mood (assessed by score on the Beck Depression Inventory (BDI)) with antidepressant treatment is assessed. BDI scores may range from 0-63, where 0 demonstrates the lowest depression score and 63 the most severe depression.
Measure: Change in mood (assessed by score on the Beck Depression Inventory) with antidepressant treatment Time: 4-6 weeks (per patient)Secondary Outcomes
Description: Changes in scores on the Clinical Global Impression scale, as assessed by the participant's general medical practitioner is recorded. This scale ranges from 0-7, where 0 is the least severely ill and 7 the most severely ill.
Measure: Change in mood with antidepressant treatment, measured by the Clinical Global Impression Scale (CGI scale) Time: 4-6 weeks (per patient)Description: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9). PHQ9 scores range from 0-27, where 0 is the score for the least depressed patients and 27 the most severely depressed patients.
Measure: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9) Time: 4-6 weeks (per patient)Description: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS). HADS scores for depression range from 0-21, where 0-7 is normal, 8-10 borderline and 11+ indicates clinical depression
Measure: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS) Time: 4-6 weeks (per patient)Description: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS). Scores for QIDS range from 0-27, where 0 indicates no symptoms of depression and 27 indicates the most severe depression.
Measure: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS) Time: 4-6 weeks (per patient)Description: A computerised algorithm will be used to direct the taste test to assess taste sensitivity. The algorithm has been developed to direct the taste test, indicating which taste solutions should be presented to the participant in which order. Every solution presented is recorded, along with answers given. These will be examined after testing to validate the code's ability to follow the algorithm created and properly determine taste thresholds.
Measure: Validation of diagnostic algorithm, comparing the sequence of taste testing determined by the device software with the algorithm described in the software specification. Time: 12 months (duration of trial)Description: User views on ease of use of the device and testing process will be collected. Users will be asked to give ease of use a score from 1-5, where 1 is very easy and 5 is very difficult. Participants will also be asked whether they would use the taste test again.
Measure: User assessment of ease of use of the device and testing process. Time: 4-6 weeks (per patient)Postnatal depression is an important problematic in French population with approximatively 10 -20% of women who suffer from postnatal depression. This pathology may have strong negative impact on both women and neonate's health. The women's satisfaction degree in front of childbirth is an important factor associated with postnatal depression since women unsatisfied of their childbirth and/or women with a complicated childbirth are more encline to suffer from postnatal depression. It is likely that the actual context of Covid 19 pandemia and the change in obstetrical cares organization may have a negative impact on women's satisfaction about their childbirth and so a negative impact on the risk of postnatal depression.
NCT04368208 Postnatal Depression Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery MeSH:Depression, Postpartum Depression Depressive Disorder
HPO:Depressivity
Primary Outcomes
Description: proportion of women with an Edinburgh score higher than 12 between 4 and 6 weeks postpartum
Measure: Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia Time: 4-6 weeks postpartum
Secondary Outcomes
Description: Existence of an association with postnatal depression and these factors: socio demographic women's characteristics, modalities of pregnancy management, satisfaction and experience about delivery, postnatal pelvic floor disorders, self rated health for the woman and the child, modalities of delivery, prenatal anxiety
Measure: Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia Time: 4-6 weeks postpartum
Description: Scale from 0 to 10 of satisfaction ; answers to the WOMBLSQ4 questionnaire about childbirth experience and satisfaction
Measure: Describe the experience and the satisfaction about delivery during the covid 19 pandemia Time: within the week after delivery
3 Descriptive Study of the PSYchological Impact of CONFinement Measures in Subjects With Mood Disorders : PsyConf
Primary Outcomes
Description: proportion of women with an Edinburgh score higher than 12 between 4 and 6 weeks postpartum
Measure: Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia Time: 4-6 weeks postpartumSecondary Outcomes
Description: Existence of an association with postnatal depression and these factors: socio demographic women's characteristics, modalities of pregnancy management, satisfaction and experience about delivery, postnatal pelvic floor disorders, self rated health for the woman and the child, modalities of delivery, prenatal anxiety
Measure: Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia Time: 4-6 weeks postpartumDescription: Scale from 0 to 10 of satisfaction ; answers to the WOMBLSQ4 questionnaire about childbirth experience and satisfaction
Measure: Describe the experience and the satisfaction about delivery during the covid 19 pandemia Time: within the week after deliveryQuarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom .It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms. Poor social contacts and history of psychiatric disorders are factors increasing the negative psychological impact of confinement. Patients with psychiatric disorders are therefore particularly vulnerable during quarantine. Only one study has reported that history of psychiatric disorder was associated with a higher risk of anxiety and anger at 4 - 6 months after the end of quarantine. Since March 17th, 2020 the French government has implemented national containment measures due to the Covid-19 epidemic. This situation has led to a reorganization of care as requested on March 22nd, 2020 in the recommendations applicable to the organization of care in psychiatric services: priority to telephone contacts and teleconsultations by multiplying contacts and assessments. As part of the telephone contacts that are now part of the recommended care, patients are systematically interviewed on the impact of the confinement situation on their psychological well-being with self-questionnaires used in the daily clinical practice. Assessing the negative psychological impact in patients with a psychiatric history is essential to better deploy post-confinement management. This assessment will provide preliminary indicators for the appropriate organization of care.
NCT04374643 Depression, Unipolar COVID 19 Other: Questionnaire to study the psychological impact of confinement MeSH:Depression Depressive Disorder Mood Disorders
HPO:Depressivity
Primary Outcomes
Description: depressive symptomatology with Patient Health Questionnaire
Measure: Depressive Symptomatology Time: during confinement
Secondary Outcomes
Description: depressive symptomatology with Patient Health Questionnaire
Measure: Depressive Symptomatology Time: post-confinement : 15 days, 3 months, 6 months
Other Outcomes
Description: Psychological pain : likert scale
Measure: Psychological pain Time: confinement
Description: quality of sleep assessed with Insomnia Seveity Index
Measure: sleep Time: confinement
Description: quality of sleep assessed with Insomnia Seveity Index
Measure: sleep Time: post-confinement (15 days, 3 months, 6 months)
Description: anxiety intensity assessed by Generalized Anxieety Disorder
Measure: anxiety Time: confinement
Description: anxiety intensity assessed by Generalized Anxieety Disorder
Measure: anxiety Time: post-confinement (15 days, 3 months, 6 months)
Description: psychological pain : likert scale
Measure: psychological pain Time: post-confinement (15 days, 3 months, 6 months)
Description: psychological pain : likert scale
Measure: physical pain Time: confinement
Description: psychological pain : likert scale
Measure: physical pain Time: post-confinement (15 days, 3 months, 6 months)
Description: staxi state scale
Measure: anger Time: confinement
Description: staxi state scale
Measure: anger Time: post-confinement (15 days, 3 months, 6 months)
Description: Assessed by the Stressful Event Impact Scale - Horowitz
Measure: Stressful Event Impact Time: confinement
Description: Assessed by the Stressful Event Impact Scale - Horowitz
Measure: Stressful Event Impact Time: post-confinement (15 days, 3 months, 6 months)
Description: declarative psychotropic drugs consumption
Measure: Use of psychotropic drugs Time: confinement
Description: declarative psychotropic drugs consumption
Measure: Use of psychotropic drugs Time: post-confinement (15 days, 3 months, 6 months)
Description: declarative consumption
Measure: Tobacco consumption Time: confinement
Description: declarative consumption
Measure: Tobacco consumption Time: post-confinement (15 days, 3 months, 6 months)
Description: declarative consumption
Measure: alcohol consumption Time: post-confinement (15 days, 3 months, 6 months)
Description: declarative consumption
Measure: alcohol consumption Time: confinement
Description: declarative consumption
Measure: Illicit substances consumption Time: confinement
Description: declarative consumption
Measure: Illicit substances consumption Time: post-confinement (15 days, 3 months, 6 months)
Description: LOT-R questionnaire
Measure: orientation of life Time: confinement
Description: LOT-R questionnaire
Measure: orientation of life Time: post-confinement (15 days, 3 months, 6 months)
4 Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic - a Web-based Cross-sectional Survey
Primary Outcomes
Description: depressive symptomatology with Patient Health Questionnaire
Measure: Depressive Symptomatology Time: during confinementSecondary Outcomes
Description: depressive symptomatology with Patient Health Questionnaire
Measure: Depressive Symptomatology Time: post-confinement : 15 days, 3 months, 6 monthsOther Outcomes
Description: Psychological pain : likert scale
Measure: Psychological pain Time: confinementDescription: quality of sleep assessed with Insomnia Seveity Index
Measure: sleep Time: confinementDescription: quality of sleep assessed with Insomnia Seveity Index
Measure: sleep Time: post-confinement (15 days, 3 months, 6 months)Description: anxiety intensity assessed by Generalized Anxieety Disorder
Measure: anxiety Time: confinementDescription: anxiety intensity assessed by Generalized Anxieety Disorder
Measure: anxiety Time: post-confinement (15 days, 3 months, 6 months)Description: psychological pain : likert scale
Measure: psychological pain Time: post-confinement (15 days, 3 months, 6 months)Description: psychological pain : likert scale
Measure: physical pain Time: confinementDescription: psychological pain : likert scale
Measure: physical pain Time: post-confinement (15 days, 3 months, 6 months)Description: staxi state scale
Measure: anger Time: confinementDescription: staxi state scale
Measure: anger Time: post-confinement (15 days, 3 months, 6 months)Description: Assessed by the Stressful Event Impact Scale - Horowitz
Measure: Stressful Event Impact Time: confinementDescription: Assessed by the Stressful Event Impact Scale - Horowitz
Measure: Stressful Event Impact Time: post-confinement (15 days, 3 months, 6 months)Description: declarative psychotropic drugs consumption
Measure: Use of psychotropic drugs Time: confinementDescription: declarative psychotropic drugs consumption
Measure: Use of psychotropic drugs Time: post-confinement (15 days, 3 months, 6 months)Description: declarative consumption
Measure: Tobacco consumption Time: confinementDescription: declarative consumption
Measure: Tobacco consumption Time: post-confinement (15 days, 3 months, 6 months)Description: declarative consumption
Measure: alcohol consumption Time: post-confinement (15 days, 3 months, 6 months)Description: declarative consumption
Measure: alcohol consumption Time: confinementDescription: declarative consumption
Measure: Illicit substances consumption Time: confinementDescription: declarative consumption
Measure: Illicit substances consumption Time: post-confinement (15 days, 3 months, 6 months)Description: LOT-R questionnaire
Measure: orientation of life Time: confinementDescription: LOT-R questionnaire
Measure: orientation of life Time: post-confinement (15 days, 3 months, 6 months)The article presents a protocol of a cross-sectional study of mental health of pregnant women in relation to the COVID 19 pandemic. The primary aim is to compare differences in anxiety and depression scores of pregnant women between countries affected by the COVID-19 pandemic. The secondary aim is to assess demographic, economic, and social aspects affecting maternal anxiety and depression scores among pregnant women worldwide in the time of the COVID-19 pandemic. Finally, investigators will be able to compare differences in perception of the different aspects of the COVID-19 pandemic (social distancing, restrictions related to delivery) between countries and according to the epidemic status (number of infected patients, number of reported deaths). The comparisons will also be done according to COVID-19 status of the participants.
NCT04377412 Anxiety Depression Pregnancy Related Other: Pandemic control measures MeSH:Depression Depressive Disorder Anxiety Disorders
HPO:Depressivity
Primary Outcomes
Description: Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points
Measure: Anxiety Time: 4 months
Description: Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points
Measure: Depression Time: 4 months
5 Impact of Covid-19 Pandemic on Depression and Quality of Life: Cross Sectional Study on Turkish Society and Suggestions on Potential Solution
Primary Outcomes
Description: Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points
Measure: Anxiety Time: 4 monthsDescription: Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points
Measure: Depression Time: 4 monthsIt is aimed to investigate the depression and quality of life of Turkish society caused by Covid-19 pandemic and reveal the relationship between them
NCT04394078 Depression Quality of Life Covid 19 Social Isolation Other: Online survey MeSH:Depression Depressive Disorder
HPO:Depressivity
Primary Outcomes
Description: Participants are asked to give information about: age, gender, educational status, height, weight, occupation, working status, city inhabited, whether they live alone or with someone, whether they have a chronic disease, have a pet, do physical activity, eat healthy and sufficient, have qualified sleep, whether they are supported economically.
Measure: Sociodemographic information form Time: two months after Covid 19 recognised as pandemic
Description: Zung depression scale, developed by Zung (Zung, 1965), is patient rating depression scale, was used to asses four domains related to depression; somatic, mood disorders, psychomotor and psychological disorders. Each question is rated on a 4-point Likert scale (0- never, 1- sometimes, 2- frequently, 3- always). Scale contains 10 straight 10 reverse questions. The total score is calculated from the raw score obtained (total score = (raw score / 80) * 100). Accordingly, scores less than 50 are normal or no psychopathology; between 50 and 59 points indicates mild level, between 60 and 69 points indicate moderate level and 70 and above points indicate severe level depression (Thurber et al., 2002). The validity reliability of the scale was studied on Turkish society (Gencdogan & Nihal, 2011)
Measure: Zung Depression Scale Time: two months after Covid 19 recognised as pandemic
Description: World Health Organization Quality of Life Bref is the short version of the WHOQOL-100 to assess the health-related quality of life (Harper et al., 1998), which has efficient psychometric properties, valid and reliable for Turkish society (Eser et al., 1999). It is essential for epidemiological survey and international report has built for psychometric properties for 26 country where Turkey within (Skevington et al., 2004). It has 4 domains; physical health, psychology, social relations and environment. Each question is answered on a 5-point Likert scale. The raw score is converted into a percentage system. The quality of life is interpreted as good as it gets closer to 100% (Akvardar et al., 2006).
Measure: World Health Organization Quality of Life - Bref Time: two months after Covid 19 recognised as pandemic
HPO Nodes
HP:0000716: Depressivity
Genes 381
TRNF ARSG FUS ANG PDE11A GLE1 SARS1 PLA2G6 NEK1 SLC18A2 HLA-DRB1 FMN2 TRNS2 XK SMPD1 HTT CHD7 ATXN10 SNCAIP TCF4 ATP1A3 GPR101 DRD2 PDGFB OPTN TWNK RRM2B GBA KCNT1 BCR JPH3 NOTCH3 PDCD1 PAH PIGC HTR2A PRKN DNMT1 TRNL1 ZC3H14 ST3GAL3 USH1G LMNB1 LIMK1 SNCA ADH1C ATRX OCRL PRKACA TBL2 FMR1 PRNP CPOX USP8 PPARGC1A UCHL1 VPS13C GLUD2 KCNJ2 TBK1 MST1 TWNK MSTO1 MAPT B3GALNT2 PPP2R2B PROKR2 PRNP XPR1 RPS20 POLG SQSTM1 ARMC5 NDST1 TRNN TARDBP USH2A TRNL2 GNAS DCPS STX16 TTC19 ATXN10 SLC20A2 TBX1 CSF1R GSN ND1 ATP7B CDH23 TAC3 MYO7A WFS1 TWNK PDGFRB HS6ST1 PRKCG ESPN COX2 HIRA GNAS CLCN4 CASR ARSA GABRA1 GCH1 DNA2 MAPT UBQLN2 GDAP2 FGF8 TOR1A SEMA4A TK2 UFD1 FUS DGUOK EPM2A HARS1 C9ORF72 POLG UNC13A PODXL TBK1 LRRK2 CLIP2 HTRA2 DCTN1 TRAPPC9 C19ORF12 PLA2G6 MATR3 C12ORF4 GRIK2 SLC6A4 PRNP MECP2 CP HLA-DQB1 CFAP410 CACNA1G MED23 AARS2 VCP TRNQ PRNP JMJD1C SRPX2 VAPB MYO7A SGCE CC2D1A VPS35 ABCA7 CCNF EHMT1 C9ORF72 SNCA MLH1 PANK2 DUSP6 CEP78 GABRB3 FIG4 NR4A2 BMPR1A PTPN22 PARK7 MECP2 DNMT1 WASHC4 TRNS1 CACNA1G AMACR VCP ALMS1 IDUA CHMP2B PMS1 GIGYF2 KISS1R TSC1 RPS6KA3 COQ2 ERBB4 KDM5B POLG2 SEC24C SLC2A1 COQ2 DNAJC13 MSTO1 MSH6 FBXO31 RRM2B CHMP2B HTT POLG EDC3 PGAP1 NSMF SLC25A4 ATXN2 PIK3CA THOC2 PER2 GLA CACNA1H TBC1D7 PAH SQSTM1 POLG GNAS PRNP AIMP1 ARMC5 CIB2 LINS1 GABRG2 FGFR1 C9ORF72 CDH23 METTL23 TACR3 EPCAM TRNS1 PPOX KRAS ANOS1 SLC45A1 WARS2 POLG FA2H COASY HLA-DQB1 GNAS TRNL1 PRSS12 CLN6 GBA PMS2 C9ORF72 CLCN4 HBB TSC2 PDGFB AIP PRKAR1A COMT MAPT DNAJC5 CRADD ATXN8 ATXN2 ATP13A2 ARVCF GTF2I WHRN GBA TRNW COX3 KISS1 TREM2 TGFBR2 PDZD7 AFG3L2 PDGFRB BCS1L MAN1B1 SNCA VCP NEFH TRNH COX1 ATP1A3 DAO CPOX PINK1 LRRK2 HMBS CRBN DCTN1 CTSF GPR35 CLIP1 TBX1 ND5 TAF15 ND4 PTS PON3 MED25 DNAJC6 TRNS2 NSUN2 FMO3 SPAST HMBS FGF17 ELN PON1 CBS CYP27A1 FGF14 PSAP FMR1 TMEM106B KCTD17 RREB1 CHCHD10 TWNK TBP AP2S1 ATXN8OS FRRS1L ATXN8OS BAZ1B HNMT FAN1 ADGRV1 PINK1 HNRNPA1 PRPH TUSC3 MBOAT7 PRNP PANK2 FGF14 GABRG2 KCTD17 PDGFRB TECR LMAN2L EIF4G1 GNAS CLRN1 EPHA4 GP1BB JRK IQSEC1 TREM2 MSH2 PSEN1 RFC2 PON2 MAPK1 SGCE PER3 PROK2 GRIN2A TNIK PFN1 MLH3 GRN ND6 CRKL ANXA11 C9ORF72 GNRHR EZR VCP USH1C GNRH1 TOR1A WFS1 POLG NHLRC1 CISD2 CHCHD10 WDR11 SPRY4 PPT1 PCDH15 TBP GTF2IRD1 SOD1 RSRC1 GLT8D1 DCTN1 GNA11 TARDBP
Primary Outcomes
Description: Participants are asked to give information about: age, gender, educational status, height, weight, occupation, working status, city inhabited, whether they live alone or with someone, whether they have a chronic disease, have a pet, do physical activity, eat healthy and sufficient, have qualified sleep, whether they are supported economically.
Measure: Sociodemographic information form Time: two months after Covid 19 recognised as pandemicDescription: Zung depression scale, developed by Zung (Zung, 1965), is patient rating depression scale, was used to asses four domains related to depression; somatic, mood disorders, psychomotor and psychological disorders. Each question is rated on a 4-point Likert scale (0- never, 1- sometimes, 2- frequently, 3- always). Scale contains 10 straight 10 reverse questions. The total score is calculated from the raw score obtained (total score = (raw score / 80) * 100). Accordingly, scores less than 50 are normal or no psychopathology; between 50 and 59 points indicates mild level, between 60 and 69 points indicate moderate level and 70 and above points indicate severe level depression (Thurber et al., 2002). The validity reliability of the scale was studied on Turkish society (Gencdogan & Nihal, 2011)
Measure: Zung Depression Scale Time: two months after Covid 19 recognised as pandemicDescription: World Health Organization Quality of Life Bref is the short version of the WHOQOL-100 to assess the health-related quality of life (Harper et al., 1998), which has efficient psychometric properties, valid and reliable for Turkish society (Eser et al., 1999). It is essential for epidemiological survey and international report has built for psychometric properties for 26 country where Turkey within (Skevington et al., 2004). It has 4 domains; physical health, psychology, social relations and environment. Each question is answered on a 5-point Likert scale. The raw score is converted into a percentage system. The quality of life is interpreted as good as it gets closer to 100% (Akvardar et al., 2006).
Measure: World Health Organization Quality of Life - Bref Time: two months after Covid 19 recognised as pandemic